Clinical trial · Observational
Safety and Efficacy Real-world Data of Trastuzumab Deruxtecan and Sacituzumab Govitecan
Safety and Efficacy Real-world Data of Trastuzumab Deruxtecan and Sacituzumab Govitecan in Patients With Advanced Breast Cancer
NCT06504719CI-TRIAL-00095158completedClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The study aims to evaluate real-world efficacy and toxicity data of treatment with Trastuzumab deruxtecan (T-DXd), a HER2-targeting ADC and sacituzumab govitecan (SG), a TROP-2-targeting ADC in pretreated patients with advanced breast cancer.
Conditions
Conditions (2)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Breast Cancer | Malignant Breast Neoplasm | CURATED_EXACT | 0.92 |
| Metastatic Cancer | Malignant Neoplasm | CURATED_BROADER | 0.78 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Antibody-Drug Conjugates | Drug | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- label
- Patients treated with trastuzumab deruxtecan or sacituzumab govitecan
- description
- Patients with TNBC, HER2-positive and/or hormone receptor positive advanced breast treated with trastuzumab deruxtecan or sacituzumab govitecan
- interventionNames
- Drug: Antibody-Drug Conjugates
Primary outcomes (1)
- measure
- The primary endpoint was toxicity rate of each drug
- timeFrame
- From the initiation of ADC to the date of discontinuation (due to any reason), first documented progression, death from any cause or last contact, throughout study completion, up to 24 months
- description
- Adverse events (AEs) were graded according to the Common Terminology Criteria for Adverse Events (CTCAE, version 5.0)
Secondary outcomes (1)
- measure
- progression-free survival (PFS)
- timeFrame
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Histologically confirmed metastatic/recurrent breast cancer * 18 years of age * Triple-negative (TNBC), HER2-positive and/or hormone receptor positive advanced breast cancer * Treatment with an ADC at any of line of treatment * Treatment with at least one cycle of T-DXd and/or SG Exclusion Criteria: * NA
References
Publications (0)
Data not yet available
No reference posted for this study.